Category Archives: Stem Cell Medicine


DO STEM CELL TREATMENTS WORK? | The Stem Cell Blog

ADULT, amputat, clinical trial, CURE, DIABETES, fda, heal, heart, MS, multiple sclerosis, PALSY, RESEARCH, stem cell, stroke, therapy, TREATMENT

DO STEM CELL TREATMENTS WORK?

Do not take one step further in your plans for treatment or read one more word about stem cells anywhere else until you believe that we have answered this question, unequivocally and without a shadow of a doubt:

Ask most US doctors if repair stem cell treatments work and they will tell you NO! You may also get condescending retorts, misinformation and derisive abuse. But if you press them on the question, eventually they will give you the reason why they believe repair stem cells dont work. The top answer WHY STEM CELLS DONT WORK is (Survey Says!):

There have been no clinical trials to date that prove they do work.

When all is said and done, in the end, there is nothing that will convince a western doctor of the effectiveness of stem cell treatments besides clinical trials. So have there been any stem cell clinical trials? Is all of the evidence supporting the benefits of stem cell treatments anecdotal as virtually every western doctor says? NOT ON YOUR LIFE! Have there been clinical trials? The answer is a resounding YES!

According to the National Institutes of Health, there were and are ~2600 stem cell clinical trials around the world http://www.clinicaltrials.gov/

Lets look at (only) a few of those ~1300 clinical trials:

Other stroke articles:

Read the original here:
DO STEM CELL TREATMENTS WORK? | The Stem Cell Blog

ViaCyte gets $20M for diabetes therapy trials

Human embryonic stem cells were differentiated into cells of the pancreas (blue). These cells give rise to insulin-producing cells (red). When implanted into mice, the stem cell-derived pancreatic cells effectively replace the insulin lost in type 1 diabetes. San Diego-based ViaCyte is developing an implantable artificial pancreas derived from human embryonic stem cells. Its work is funded in part by grants from the California Institute for Regenerative Medicine.

San Diego's ViaCyte has received $20 million from a drug company to advance its stem cell-based therapy for type 1 diabetes into clinical trials.

ViaCyte's agreement with Janssen Pharmaceuticals, a Johnson & Johnson company, comes days after the company announced receiving the go-ahead from the U.S. Food and Drug Administration to begin clinical trials. The agreement also includes the company's investment fund, Johnson & Johnson Development Corporation.

ViaCyte's experimental product, VC-01, is derived from human embryonic stem cells. These cells are matured into cells that regulate blood sugar levels. These includes cells that make insulin, which lowers blood sugar, in addition to cells that make glucagon, which raises blood sugar levels. It's believed that recreating this natural complement of hormones will be more effective than administering insulin alone.

The cells are encapsulated into a semi-permeable pouch that allows the hormones to enter the bloodstream, and nutrients from the bloodstream to enter cells, but keeps out the immune system, which would otherwise attack the cells.

The California Institute for Regenerative Medicine (CIRM), the states stem cell agency, has awarded ViaCyte more than $38 million to help develop the treatment over the past six years.

The money will mostly be used to advance clinical development of the product, ViaCyte said. The agreement also gives Janssen the right to "consider a longer-term transaction" related to the product.

This is excellent news as it demonstrates that pharmaceutical companies are recognizing stem cell therapies hold tremendous promise and need to be part of their development portfolio, CIRM president and CEO C. Randal Mills said in a statement. This kind of serious financial commitment from industry is vital in helping get promising therapies like this through all the phases of clinical trials and, most importantly, to the patients in need.

ViaCyte had also recently received $5.4 million in private equity financing.

These important transactions provide us with the additional resources we need to pursue the further development of the VC-01 product candidate as a potential new treatment option for patients with type 1 diabetes, said Paul Laikind, Ph.D., ViaCyte's president and CEO, in the statement. We are pleased to be extending our relationship with Janssen and JJDC is this area of mutual interest.

Go here to read the rest:
ViaCyte gets $20M for diabetes therapy trials

VIACYTE CLINICAL TRIAL OKD

By Bradley J. Fikes U-T5:06 a.m.Aug. 20, 2014

ViaCyte of San Diego has received permission from the Food and Drug Administration to try its stem cell-based diabetes therapy.

The combination clinical trial phases 1 and 2 will aim to determine the safety level of the therapy and look for early signs of efficacy.

ViaCyte grows replacement insulin-producing cells from human embryonic stem cells, which are placed in a semipermeable pouch. The pouch will be implanted into patients, allowing insulin and other hormones to enter their bloodstream. The pouch and cells are together called VC-01.

The product has the potential to provide a virtual cure for Type 1 diabetes, ViaCyte officials said.

Clinical testing in animals has shown that the replacement cells successfully duplicate the function of insulin-producing beta cells. They secrete not only insulin, which lowers blood sugar, but hormones such as glucagon, which raises it. Providing a range of hormones as in the natural pancreas is expected to provide better control of blood sugar than with insulin alone.

The FDA green light is not only good news for privately held ViaCyte, but also for the states stem cell agency, the California Institute for Regenerative Medicine. The agency, which has granted ViaCyte more than $38 million to research and develop the treatment, has been under pressure in recent years to show that its $3 billion in bond funding is leading to therapies.

(The institute) was created to help develop stem cell treatments for diseases that are currently incurable with traditional approaches, C. Randal Mills, president and CEO of the agency, said in a statement. Anytime a product, particularly one as innovative as this one, progresses from the lab and into clinical trials, its very encouraging news.

Inadequate control of blood sugar increases the risk of heart disease, stroke, kidney failure and other complications from diabetes.

The ViaCyte product contains immature beta cells grown from embryonic stem cells. After implantation, the cells mature and begin to release the appropriate hormones in response to blood sugar levels.

More:
VIACYTE CLINICAL TRIAL OKD

Stem cell study reveals how genetic variations linked to mental illness affects neuron

A new study of stem cells has revealed how a genetic variation linked to schizophrenia, bipolar disorder and severe depression affects connections among neurons in the developing brain.

According to the study led by Guo-li Ming and Hongjun Song of the Johns Hopkins University School of Medicine, using stem cells generated from people with and without mental illness to observe the effects of a rare and pernicious genetic variation on young brain cells found that several major mental illnesses have common roots in faulty "wiring" during early brain development.

Ming said that this was the next best thing to going back in time to see what happened while a person was in the womb to later cause mental illness and they found the most convincing evidence yet that the answer lies in the synapses that connect brain cells to one another.

One difficulty in studying the genetics of common mental illnesses is that they are generally caused by environmental factors in combination with multiple gene variants, any one of which usually could not by itself cause disease. A rare exception is the gene known as disrupted in schizophrenia 1 (DISC1), in which some mutations have a strong effect. Two families have been found in which many members with the DISC1 mutations have mental illness.

To find out how a DISC1 variation with a few deleted DNA "letters" affects the developing brain, the research team collected skin cells from a mother and daughter in one of these families who have neither the variation nor mental illness, as well as the father, who has the variation and severe depression, and another daughter, who carries the variation and has schizophrenia. For comparison, they also collected samples from an unrelated healthy person. Postdoctoral fellow Zhexing Wen, Ph.D., coaxed the skin cells to form five lines of stem cells and to mature into very pure populations of synapse-forming neurons.

After growing the neurons in a dish for six weeks, collaborators at Pennsylvania State University measured their electrical activity and found that neurons with the DISC1 variation had about half the number of synapses as those without the variation.

To find out how DISC1 acts on synapses, the researchers also compared the activity levels of genes in the healthy neurons to those with the variation and found that the activities of more than 100 genes were different and the researchers added that this is the first indication that DISC1 regulates the activity of a large number of genes, many of which are related to synapses.

The study was published online in the journal Nature.

(Posted on 18-08-2014)

Read the original here:
Stem cell study reveals how genetic variations linked to mental illness affects neuron

Stem cells reveal how illness-linked genetic variation affects neurons

A genetic variation linked to schizophrenia, bipolar disorder and severe depression wreaks havoc on connections among neurons in the developing brain, a team of researchers reports. The study, led by Guo-li Ming, M.D., Ph.D., and Hongjun Song, Ph.D., of the Johns Hopkins University School of Medicine and described online Aug. 17 in the journal Nature, used stem cells generated from people with and without mental illness to observe the effects of a rare and pernicious genetic variation on young brain cells. The results add to evidence that several major mental illnesses have common roots in faulty "wiring" during early brain development.

"This was the next best thing to going back in time to see what happened while a person was in the womb to later cause mental illness," says Ming. "We found the most convincing evidence yet that the answer lies in the synapses that connect brain cells to one another."

Previous evidence for the relationship came from autopsies and from studies suggesting that some genetic variants that affect synapses also increase the chance of mental illness. But those studies could not show a direct cause-and-effect relationship, Ming says.

One difficulty in studying the genetics of common mental illnesses is that they are generally caused by environmental factors in combination with multiple gene variants, any one of which usually could not by itself cause disease. A rare exception is the gene known as disrupted in schizophrenia 1 (DISC1), in which some mutations have a strong effect. Two families have been found in which many members with the DISC1 mutations have mental illness.

To find out how a DISC1 variation with a few deleted DNA "letters" affects the developing brain, the research team collected skin cells from a mother and daughter in one of these families who have neither the variation nor mental illness, as well as the father, who has the variation and severe depression, and another daughter, who carries the variation and has schizophrenia. For comparison, they also collected samples from an unrelated healthy person. Postdoctoral fellow Zhexing Wen, Ph.D., coaxed the skin cells to form five lines of stem cells and to mature into very pure populations of synapse-forming neurons.

After growing the neurons in a dish for six weeks, collaborators at Pennsylvania State University measured their electrical activity and found that neurons with the DISC1 variation had about half the number of synapses as those without the variation. To make sure that the differences were really due to the DISC1 variation and not to other genetic differences, graduate student Ha Nam Nguyen spent two years making targeted genetic changes to three of the stem cell lines.

In one of the cell lines with the variation, he swapped out the DISC1 gene for a healthy version. He also inserted the disease-causing variation into one healthy cell line from a family member, as well as the cell line from the unrelated control. Sure enough, the researchers report, the cells without the variation now grew the normal amount of synapses, while those with the inserted mutation had half as many.

"We had our definitive answer to whether this DISC1 variation is responsible for the reduced synapse growth," Ming says.

To find out how DISC1 acts on synapses, the researchers also compared the activity levels of genes in the healthy neurons to those with the variation. To their surprise, the activities of more than 100 genes were different. "This is the first indication that DISC1 regulates the activity of a large number of genes, many of which are related to synapses," Ming says.

The research team is now looking more closely at other genes that are linked to mental disorders. By better understanding the roots of mental illness, they hope to eventually develop better treatments for it, Ming says.

More here:
Stem cells reveal how illness-linked genetic variation affects neurons

Transparent Fish Lead to Stem Cell Research Breakthrough

brindafella (702231) writes Australian scientists have accidentally made one of the most significant discoveries in stem cell research, by studying the transparent embryos of Zebrafish (Danio rerio). The fish can be photographed and their development studied over time, and the movies can be played backwards, to track back from key developmental stages to find the stem cell basis for various traits of the fish. This fundamental research started by studying muscles, but the blood stem cell breakthrough was a bonus. They've found out how hematopoietic stem cells (HSC), among the most important stem cells found in blood and bone marrow, is formed. The scientists are based at the Australian Regenerative Medicine Institute at Monash University. The research has been published in the Nature medical journal. This discovery could lead to the production of self-renewing stem cells in the lab to treat multiple blood disorders and diseases.

See more here:
Transparent Fish Lead to Stem Cell Research Breakthrough

New Blood: Tracing the Beginnings of Hematopoietic Stem Cells

Contact Information

Available for logged-in reporters only

Newswise Hematopoietic stem cells (HSCs) give rise to all other blood cell types, but their development and how their fate is determined has long remained a mystery. In a paper published online this week in Nature, researchers at the University of California, San Diego School of Medicine elaborate upon a crucial signaling pathway and the role of key proteins, which may help clear the way to generate HSCs from human pluripotent precursors, similar to advances with other kinds of tissue stem cells.

Principal investigator David Traver, PhD, professor in the Department of Cellular and Molecular Medicine, and colleagues focused on the Notch signaling pathway, a system found in all animals and known to be critical to the generation of HSCs in vertebrates. Notch signaling between emitting and receiving cells is key to establishing HSC fate during development, said Traver. What has not been known is where, when and how Notch signal transduction is mediated.

Traver and colleagues discovered that the Notch signal is transduced into HSC precursor cells from signal emitting cells in the somite embryologic tissues that eventually contribute to development of major body structures, such as skeleton, muscle and connective tissues much earlier in the process than previously anticipated.

More specifically, they found that JAM proteins, best known for helping maintain tight junctions between endothelial cells to prevent vascular leakage, were key mediators of Notch signaling. When the researchers caused loss of function in JAM proteins in a zebrafish model, Notch signaling and HSCs were also lost. When they enforced Notch signaling through other means, HSC development was rescued.

To date, it has not been possible to generate HSCs de novo from human pluripotent precursors, like induced pluripotent stem cells, said Traver. This has been due in part to a lack of understanding of the complete set of factors that the embryo uses to make HSCs in vivo. It has also likely been due to not knowing in what order each required factor is needed.

Our studies demonstrate that Notch signaling is required much earlier than previously thought. In fact, it may be one of the earliest determinants of HSC fate. This finding strongly suggests that in vitro approaches to instruct HSC fate from induced pluripotent stem cells must focus on the Notch pathway at early time-points in the process. Our findings have also shown that JAM proteins serve as a sort of co-receptor for Notch signaling in that they are required to maintain close contact between signal-emitting and signal-receiving cells to permit strong activation of Notch in the precursors of HSCs.

The findings may have far-reaching implications for eventual development of hematopoietic stem cell-based therapies for diseases like leukemia and congenital blood disorders. Currently, it is not possible to create HSCs from differentiation of embryonic stem cells or induced pluripotent stem cells pluripotent cells artificially derived from non-pluripotent cells, such as skin cells that are being used in other therapeutic research efforts.

Co-authors include Isao Kobayashi, Jingjing Kobayashi-Sun, Albert D. Kim and Claire Pouget, UC San Diego Department of Cellular and Molecular Medicine; Naonobu Fujita, UC San Diego Section of Cell and Developmental Biology; and Toshio Suda, Keio University, Japan.

Read the original post:
New Blood: Tracing the Beginnings of Hematopoietic Stem Cells

Cellular Dynamics reports higher quarterly revenues and bigger losses

Cellular Dynamics International said revenues for the quarter that ended June 30 rose nearly 30 percent over the same quarter last year but expenses jumped even more quickly.

The Madison stem cell company reported a net loss of $8.6 million, or 54 cents a share, on $3.6 million in revenues for the most recent quarter compared with a $5.1 million net loss, or $2.92 a share, on revenues of $2.8 million for the same period last year.

Costs rose because of higher research and development expenses related to CDI's contract to set up a stem cell bank with the California Institute for Regenerative Medicine, San Francisco, and to higher expenses resulting from CDI's initial public stock offering in July 2013, the company said.

At the same time, CDI said, it has manufactured stem cells for 179 customers in the past 12 months, up from 136 customers in the previous year, and the largest customers increased their purchases by 45 percent.

"We intend to achieve profitability in the long term," said the company, which was founded in 2004 by UW-Madison stem cell pioneer James Thomson.

Read more:
Cellular Dynamics reports higher quarterly revenues and bigger losses

102.29 /$ (5 p.m.)

WASHINGTON A U.S. researcher who co-authored controversial papers on stem cell development will quit his post at Brigham and Womens Hospital in Boston on Sept. 1, the institution said Tuesday.

Charles Vacanti, chairman of the hospitals Department of Anesthesiology, Preoperative and Pain Medicine, was involved in the publication by a Japanese institution of two theses on so-called STAP cells whose credibility came into question earlier this year.

Vacanti, known as a mentor of Haruko Obokata at the Japanese government-affiliate Riken institute who is a key author of the papers, will remain on faculty, the Boston hospital said.

Following a one-year sabbatical Vacanti intends to focus his energies on regenerative medicine and mentoring the next generation of anesthesiologists, the hospital said.

It remains unknown if his latest step is linked with the STAP cell controversy.

According to a U.S.-based expert on regenerative medicine, Vacanti of Harvard Medical School is believed to have written an email informing his colleagues and others of his intention to resign from the post.

Paul Knoepfler, associate professor at the University of Californias Davis School of Medicine, released Vacantis email on his blog on Monday.

It is with somewhat mixed emotions that I share with you my decision to step down, it reads.

Vacanti did not mention whether his decision has to do with his involvement in the papers on STAP cells that were published in the British science journal Nature in January and retracted in July after critical errors were found.

I plan to take a one-year sabbatical to contemplate my future goals, redirect my efforts and spend time doing some of the things that I enjoy most, the email says.

Original post:
102.29 /$ (5 p.m.)

How Breast Cancer Usurps the Powers of Mammary Stem Cells

Contact Information

Available for logged-in reporters only

Newswise During pregnancy, certain hormones trigger specialized mammary stem cells to create milk-producing cells essential to lactation. Scientists at the University of California, San Diego School of Medicine and Moores Cancer Center have found that mammary stem cells associated with the pregnant mammary gland are related to stem cells found in breast cancer.

Writing in the August 11, 2014 issue of Developmental Cell, David A. Cheresh, PhD, Distinguished Professor of Pathology and vice-chair for research and development, Jay Desgrosellier, PhD, assistant professor of pathology and colleagues specifically identified a key molecular pathway associated with aggressive breast cancers that is also required for mammary stem cells to promote lactation development during pregnancy.

By understanding a fundamental mechanism of mammary gland development during pregnancy, we have gained a rare insight into how aggressive breast cancer might be treated, said Cheresh. This pathway can be exploited. Certain drugs are known to disrupt this pathway and may interfere with the process of breast cancer progression.

During pregnancy, a new mammary stem cell population arises, distinct from those involved in development and maintenance of the non-pregnant gland. These stem cells remodel the breasts and lactating glands in preparation for feeding the newborn child. Normally, these stem cells contribute only to early remodeling events and are switched off by the time milk production begins.

The researchers found, however, that signals regulating stem cell activation during pregnancy appear to be hijacked by cancer cells to produce faster-growing, more aggressive tumors. This normal pathway ends up contributing to the progression of cancer, said Desgrosellier, first author of the study.

A connection between pregnancy and breast cancer has long been known. But the association between pregnancy and breast cancer risk is complex. While having a child reduces a womans risk of developing breast cancer later in life, there is also an increased short-term risk for the development of a highly aggressive form of breast cancer following each pregnancy. The current study suggests that molecules important for stem cell behavior during pregnancy may contribute to these more aggressive pregnancy-associated breast cancers, a possibility the researchers plan to investigate further.

The authors are quick to point out that their findings should not be interpreted as a reason to avoid pregnancy. The signaling pathway usurped by cancer cells is not the cause of breast cancer. Rather, they said, it may worsen or accelerate a cancer caused by other factors, such as an underlying mutation or genetic predisposition.

Our work doesnt speak to the actual cause of cancer. Rather, it explains what can happen once cancer has been initiated, said Cheresh. Heres an analogy: To get cancer, you first have to start with an oncogene, a gene that carries a mutation and has the potential to initiate cancer. Think of the oncogene as turning on a cars ignition. The signaling pathway exploited by cancer cells is like applying gas. It gets the car moving, but it means nothing if the oncogene hasnt first started the process.

See the original post here:
How Breast Cancer Usurps the Powers of Mammary Stem Cells